Does Medicare cover the cost of the Oncotype DX test?
The Medicare contractor responsible for processing claims submitted by Genomic Health has issued a coverage policy to cover the Oncotype DX test when used within six months of the original diagnosis for women with Stage I or II, estrogen receptor-positive, lymph node-negative breast cancer. This coverage policy applies to most Medicare beneficiaries who are eligible for the test. Currently, Medicare requires no co-payments for this type of testing. Therefore, when Medicare covers the test, the beneficiary has no financial obligation (unless the annual deductible applies).
Yes, Medicare covers claims submitted by Genomic Health when used within six months of the original diagnosis for women with stage I or II, estrogen-receptor-positive, lymphnode-negative breast cancer. This coverage policy applies to most Medicare beneficiaries who are eligible for the test. Currently, Medicare requires no co-payments for this type of testing. Therefore, when Medicare covers the test, the beneficiary has no financial obligation (unless the annual deductible applies). For additional information regarding insurance coverage call 866-ONCOTYPE (866-662-6897).
